Ungrounded speculation or reasonable caution? Both are present in this Newsweek story on two very early trials of immunotherapy drugs being developed to protect against melanoma. While the headline calls the research “a cancer breakthrough,” quotes from researchers bring some much-need focus on the studies’ limitations.
These are — after all — phase 1 safety trials with just six volunteers in one and 13 in the other. Far too small a group to make any claims about successful results. The article does tell readers what questions remain about the vaccines (such as do they extend life and how effective are they compared with other treatments), and the type of research studies that are needed to answer these questions. However, noticeably absent from the story is a discussion about the exorbitant price tag associated with immunotherapy.
We’re seeing a lot of health news and PR releases devoted to immunotherapy trials so we’ve put together some tips for covering news on cancer immunotherapy drugs.
Results from small, preliminary studies like these involving six and 13 volunteers should be viewed cautiously.
Information about the effectiveness of a treatment is of limited consequence if patients cannot afford the treatment. There needs to be a discussion of cost so patients can determine whether such treatment is even possible for them.
This story doesn’t discuss how much the vaccines cost. Therefore, readers can’t compare the affordability of these vaccines to existing treatment options.
The story says that four of the six patients had no cancer recurrence after 25 months in the first study, and in the second study, eight of the 13 patients remained tumor free after 23 months.
But the studies cited are both phase I clinical trials designed to address safety, not efficacy. Any claims regarding the latter, especially given the limited number of subjects, would be highly speculative. Therefore, the headline is misleading. As noted in the final sentence of the article:
“… The next step will be to test these personalized vaccines in larger clinical trials to see if they are better than existing treatments, if they improve survival, and what their long-term side effects could be.”
We give the story credit for making an important point that waiting for the vaccine to be made might be detrimental to patients with advanced cancer. It says, “As the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment—approximately four months—which may be too long from some patients with advanced cancer.”
The story also notes that “Both vaccines were deemed safe” but it doesn’t discuss any side effects that may have shown up in the trials. What happened to the five patients who were not tumor free at 25 months?
The story does mention that more research is needed to identify potential harms.
The story mentions the types of studies that were conducted and the size of the trials. Both of these factors impact the claims that can be made from the research. And that’s important because the claims made seem out-sized compared to the very preliminary nature of the research. Phase I clinical trials are used to look at safety and side effects, not to make conclusions about the future success of personalized medicine.
To its credit, the article includes a very important quote from one of the study authors that clarifies that no conclusions should be drawn from these preliminary studies:
“It is still unknown whether these vaccines will extend the survival of cancer patients, or whether they are more effective than other recently developed immunotherapies. Additional clinical trials will be required to determine the utility of these individualised neoepitope vaccines.”
There is no evidence of disease mongering in this story.
The story incorporates insights from a few independent sources. This gives readers additional information about how the findings should be interpreted. However, no information is provided about potential conflicts of interest.
The story doesn’t mention any other treatment options for melanoma by name but states that additional research is needed to determine the effectiveness of these vaccines in comparison to existing options.
The story could have been improved by including information about the prevalence of cancer recurrence among cancer patients using existing treatment options such as surgery and chemotherapy.
One of the trials described was conducted in people who had had surgery and no other treatment options. It would have been helpful to include the length of time to tumor recurrence in people who had not received any other interventions.
Although not explicitly stated, most readers will understand that the vaccines are not currently available and have to undergo a lot more testing before they are available — if ever.
The article discusses what is and isn’t new about the research in this section: “Cancer vaccines that are personalized to the patient—designed to help the immune system identify tumors as foreign bodies and destroy them—have been considered as a potential treatment for a number of years. But working out the unique mutations of each person’s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.”
The story includes independent sources and does not appear to be reliant on a news release.
Ungrounded speculation or reasonable caution? Both are present in this Newsweek story on two very early trials of immunotherapy drugs being developed to protect against melanoma. While the headline calls the research “a cancer breakthrough,” quotes from researchers bring some much-need focus on the studies’ limitations.
These are — after all — phase 1 safety trials with just six volunteers in one and 13 in the other. Far too small a group to make any claims about successful results. The article does tell readers what questions remain about the vaccines (such as do they extend life and how effective are they compared with other treatments), and the type of research studies that are needed to answer these questions. However, noticeably absent from the story is a discussion about the exorbitant price tag associated with immunotherapy.
We’re seeing a lot of health news and PR releases devoted to immunotherapy trials so we’ve put together some tips for covering news on cancer immunotherapy drugs.
Results from small, preliminary studies like these involving six and 13 volunteers should be viewed cautiously.
Information about the effectiveness of a treatment is of limited consequence if patients cannot afford the treatment. There needs to be a discussion of cost so patients can determine whether such treatment is even possible for them.
This story doesn’t discuss how much the vaccines cost. Therefore, readers can’t compare the affordability of these vaccines to existing treatment options.
The story says that four of the six patients had no cancer recurrence after 25 months in the first study, and in the second study, eight of the 13 patients remained tumor free after 23 months.
But the studies cited are both phase I clinical trials designed to address safety, not efficacy. Any claims regarding the latter, especially given the limited number of subjects, would be highly speculative. Therefore, the headline is misleading. As noted in the final sentence of the article:
“… The next step will be to test these personalized vaccines in larger clinical trials to see if they are better than existing treatments, if they improve survival, and what their long-term side effects could be.”
We give the story credit for making an important point that waiting for the vaccine to be made might be detrimental to patients with advanced cancer. It says, “As the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment—approximately four months—which may be too long from some patients with advanced cancer.”
The story also notes that “Both vaccines were deemed safe” but it doesn’t discuss any side effects that may have shown up in the trials. What happened to the five patients who were not tumor free at 25 months?
The story does mention that more research is needed to identify potential harms.
The story mentions the types of studies that were conducted and the size of the trials. Both of these factors impact the claims that can be made from the research. And that’s important because the claims made seem out-sized compared to the very preliminary nature of the research. Phase I clinical trials are used to look at safety and side effects, not to make conclusions about the future success of personalized medicine.
To its credit, the article includes a very important quote from one of the study authors that clarifies that no conclusions should be drawn from these preliminary studies:
“It is still unknown whether these vaccines will extend the survival of cancer patients, or whether they are more effective than other recently developed immunotherapies. Additional clinical trials will be required to determine the utility of these individualised neoepitope vaccines.”
There is no evidence of disease mongering in this story.
The story incorporates insights from a few independent sources. This gives readers additional information about how the findings should be interpreted. However, no information is provided about potential conflicts of interest.
The story doesn’t mention any other treatment options for melanoma by name but states that additional research is needed to determine the effectiveness of these vaccines in comparison to existing options.
The story could have been improved by including information about the prevalence of cancer recurrence among cancer patients using existing treatment options such as surgery and chemotherapy.
One of the trials described was conducted in people who had had surgery and no other treatment options. It would have been helpful to include the length of time to tumor recurrence in people who had not received any other interventions.
Although not explicitly stated, most readers will understand that the vaccines are not currently available and have to undergo a lot more testing before they are available — if ever.
The article discusses what is and isn’t new about the research in this section: “Cancer vaccines that are personalized to the patient—designed to help the immune system identify tumors as foreign bodies and destroy them—have been considered as a potential treatment for a number of years. But working out the unique mutations of each person’s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.”
The story includes independent sources and does not appear to be reliant on a news release.
Systematic, Criteria-Driven
Don’t believe everything you hear, kids.
“What in the world justifies rushing a 348-word story to publication on a Sunday without doing extra research and reporting? Just because a scientist said it? COVID-19 journalism that devolves to that level of dreck is dangerous.”
🔥👇 https://twitter.com/garyschwitzer/status/1268175065478320131
.@Reuters: why rush to publish a 348-word story claiming #COVID19 is losing potency without doing extra research and reporting? Just because a scientist said it? #COVID19 journalism that devolves to that level of dreck is dangerous. https://www.healthnewsreview.org/2020/06/reuters-report-is-another-classic-case-study-in-how-not-to-cover-covid-19-news/
For some time our website has been subjected to malicious hacker attacks from several countries. So many that we were forced to block entry. We revisit the severity of attack regularly. When it eases, we will lift the blockade. Thanks for your understanding.
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like